Member Info for Lebus

Already corrected

Did you see many gainers yesterday?

Yep, and reasons to be cheerful.

The last few days has seen a lot of profit taking and yet the sp stands firm, which is encouraging We must surely be due Proleukin news soon?

“The patients loved it”, said RM in his interview with the Telegraph. Cant imagine them loving it unless the treatment improved their medical condition. This is RM in an upbeat mood giving a hint of the positive news to come

More buys than sells, bigger numbers involved, and a steady uptick follows. It’s just maths. We have a nice base now so cmon Iovance

Advent interest was short lived and it was all pretty vague wasn’t it. Who knows though. Hopefully Iovance update soon and Synairgen partnership is getting interesting as their Phase 3 gets under way. Clinigen continues to generate a profit and pay us a dividend. Not many AIM listed businesses can say the same. Been a good week.

Yep - makes for a nice change.

Reported in Daily Telegraph today but without mentioning the Company by name

So, expectation was that licence application would be submitted late 2020. Now anticipated 2021 but no more specific than that.

Thanks for posting that report godshare. At least it explains today’s drop.

Such is life in the Alternative Investment Market. It’s volatile. Sharp unexplained fluctuations happen.

The drug in question had hugely promising phase 2 results announced late July which attracted international publicity and a mention from Matt Han**** in the House of Commons. The SP multiplied x4 although there has been a gradual decline since then on new news. It is a small Company consisting of around 16 staff members. Great science and an impressive CEO but needs help from the big boys if they are going to get their product on the shelves

Synairgen. Check their message board and that will tell you all you need to know.

Health Secretary tells hospitals to clear beds in time for COVID second wave in two weeks.

Adds even greater urgency to the need for therapeutics

Proleukin trial impacted by pandemic. Forecast sluggish growth 1H 2021. In the absence of a bid for the Company then yeh, unwise to anticipate any significant increase in SP in the short term but hey, AIM is a volatile beast

I’m comfortable holding and looking forward to cash generating Proleukin news in 2021 and the promised accelerated growth in 2022.

14% increase in full year dividend. Nice but I would have preferred to have seen a reduction in debt instead.

Organic growth forecast to continue then, and and any positive Proleukin news will really fire the burners

EPS up 20%
Net debt to increase 1 H 2021
Organic growth forecast at lower end of 5% - 10% range 2021 with accelerated growth 2022. Well, I reckon 5% growth seen against the backdrop of Covid would be on the wish list of most businneses

Proleukin trial update hopefully

So did you decide to buy more or hold off Jatw? You were having a conversation with yourself last time you posted haha. Looking forward to results next week.

Time for pharma to scrutinise COPD data and then finalise terms